MigVax, Ltd.
MigVax Ltd. is a biotechnology company established in 2020, focused on developing innovative oral subunit vaccines for humans, starting with COVID-19. The company leverages advanced methodologies and a multidisciplinary research team to create vaccines that activate all arms of the immune system, offering comprehensive protection. It aims to address logistical challenges of current vaccines and provide safer, more accessible options, including oral and protein-based formulations.
Industries
Nr. of Employees
small (1-50)
Products
Oral subunit SARS-CoV-2 vaccine candidate (orally dissolving tablet)
A protein-based oral subunit vaccine candidate formulated as an orally dissolving tablet intended to induce mucosal (IgA), systemic (neutralizing IgG) and cellular immunity; comprised of antigenic domains and a mucosal adjuvant/carrier fused or co-administered with antigens and evaluated in preclinical models as a booster after injected priming.
Oral subunit SARS-CoV-2 vaccine candidate (orally dissolving tablet)
A protein-based oral subunit vaccine candidate formulated as an orally dissolving tablet intended to induce mucosal (IgA), systemic (neutralizing IgG) and cellular immunity; comprised of antigenic domains and a mucosal adjuvant/carrier fused or co-administered with antigens and evaluated in preclinical models as a booster after injected priming.
Services
Vaccine R&D and preclinical development
Collaborative research and development services for protein subunit vaccine candidates, including antigen design, preclinical immunogenicity and safety testing, and formulation development.
Lyophilized orally disintegrating tablet formulation development (collaborative)
Development of freeze-dried orally disintegrating tablet vaccine formulations in partnership with contract development organizations to enable room-temperature-stable oral dosing formats.
Vaccine R&D and preclinical development
Collaborative research and development services for protein subunit vaccine candidates, including antigen design, preclinical immunogenicity and safety testing, and formulation development.
Lyophilized orally disintegrating tablet formulation development (collaborative)
Development of freeze-dried orally disintegrating tablet vaccine formulations in partnership with contract development organizations to enable room-temperature-stable oral dosing formats.
Expertise Areas
- Oral vaccine development
- Mucosal immunology
- Protein subunit and chimeric antigen design
- Preclinical immunogenicity and safety testing
Key Technologies
- Protein subunit vaccine platforms
- Chimeric multiepitope antigen design
- Mucosal adjuvant delivery (bacterial toxin B subunit)
- Artificial neural networks for sequence/structure analysis